Boston Trust Walden Corp Lowers Stock Holdings in ICU Medical, Inc. (NASDAQ:ICUI)

Boston Trust Walden Corp lessened its stake in shares of ICU Medical, Inc. (NASDAQ:ICUI) by 2.8% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 317,246 shares of the medical instruments supplier’s stock after selling 9,056 shares during the quarter. Boston Trust Walden Corp owned about 1.30% of ICU Medical worth $49,227,000 at the end of the most recent quarter.

Several other hedge funds have also recently modified their holdings of the stock. Barclays PLC raised its stake in shares of ICU Medical by 15.6% during the 3rd quarter. Barclays PLC now owns 59,207 shares of the medical instruments supplier’s stock worth $10,790,000 after buying an additional 8,010 shares in the last quarter. LMR Partners LLP purchased a new position in ICU Medical in the third quarter worth $3,884,000. Principal Financial Group Inc. lifted its holdings in ICU Medical by 24.6% in the third quarter. Principal Financial Group Inc. now owns 126,937 shares of the medical instruments supplier’s stock valued at $23,130,000 after acquiring an additional 25,031 shares during the period. MetLife Investment Management LLC boosted its position in shares of ICU Medical by 129.1% during the 3rd quarter. MetLife Investment Management LLC now owns 12,389 shares of the medical instruments supplier’s stock worth $2,258,000 after purchasing an additional 6,981 shares in the last quarter. Finally, Geode Capital Management LLC grew its stake in shares of ICU Medical by 9.6% during the 3rd quarter. Geode Capital Management LLC now owns 546,954 shares of the medical instruments supplier’s stock worth $99,687,000 after purchasing an additional 48,106 shares during the period. 96.10% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of research firms recently commented on ICUI. KeyCorp boosted their price objective on shares of ICU Medical from $198.00 to $209.00 and gave the stock an “overweight” rating in a report on Wednesday, November 13th. Needham & Company LLC restated a “hold” rating on shares of ICU Medical in a report on Wednesday, November 13th. StockNews.com raised ICU Medical from a “hold” rating to a “buy” rating in a report on Wednesday, November 20th. Finally, Jefferies Financial Group raised ICU Medical from a “hold” rating to a “buy” rating and set a $200.00 target price on the stock in a report on Wednesday, December 11th. One investment analyst has rated the stock with a hold rating and four have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $199.67.

Insider Transactions at ICU Medical

In other news, CEO Vivek Jain sold 1,373 shares of the business’s stock in a transaction that occurred on Thursday, January 2nd. The shares were sold at an average price of $155.48, for a total value of $213,474.04. Following the completion of the transaction, the chief executive officer now owns 104,593 shares of the company’s stock, valued at $16,262,119.64. The trade was a 1.30 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, COO Christian B. Voigtlander sold 1,962 shares of the company’s stock in a transaction that occurred on Monday, November 25th. The shares were sold at an average price of $169.08, for a total transaction of $331,734.96. The disclosure for this sale can be found here. Insiders sold a total of 17,737 shares of company stock valued at $2,879,752 over the last three months. 6.70% of the stock is currently owned by insiders.

ICU Medical Trading Down 3.4 %

Shares of ICU Medical stock opened at $158.69 on Tuesday. ICU Medical, Inc. has a 1 year low of $86.80 and a 1 year high of $196.26. The company has a debt-to-equity ratio of 0.75, a current ratio of 2.29 and a quick ratio of 1.03. The business has a 50 day moving average price of $160.80 and a 200 day moving average price of $162.77. The company has a market capitalization of $3.88 billion, a P/E ratio of -34.72 and a beta of 0.63.

About ICU Medical

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.